The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
By J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. L. Le Beau, E. Hellström-Lindberg, A. Tefferi and 1 more. Blood, 2009
4,767 citations recorded by the source corpus.
Subfields: Emergency Medicine, Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/0e6fab46796aa350886328a0d034dbc1b517459c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. (2016, background): “The karyotype was 46,XX,t(4;11)(q21;q23),add(9)(p12)[cp20], and FISH studies showed that 83.”
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017, neutral): “Age, median (range), y 67 (19-100) 67 (19-100) 70 (19-100)”
- Translating RNA sequencing into clinical diagnostics: opportunities and challenges (2016, positive): “According to the 2008 WHO (World Health Organization) classification, diagnosis of acute myeloid leukaemia (AML) can be made regardless of blast count based on detection of recurrent genetic abnormalities, such as the t(8;21)(q22;q22) translocation, RUNX1-RUNX1T1 fusion (involving isoforms of runt-r”
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. (2014, neutral): “Neutrophils (10(9)/L) average (range) 9 (2-36) 6 (3-16) 8 (3-21)”
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. (2015, methodology): “Minimal diagnostic criteria forMDS published by theWorld Health Organization (WHO; 2008 classification, currently undergoing a revision to be released in 2016) require the presence of blood cytopenias and exclusion of reactive or other nonhematopoietic causes of those cytopenias.(46) In addition, $1”
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, methodology): “This WHO classification was further refined in 2008.(88) This revised classification allowed a more precise subclassification of patients with unilineage dysplasia.”
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network (2011, background): “…that the rapid rate of progress in understanding tumour biology, and the introduction of new diagnostic technologies and treatments mean WHO classifications, will inevitably require ongoing revision (World Health Organization, 2001; WHO, 2008; Jaffe, 2009; Vardiman et al, 2009; Campo et al, 2011).”